Clinical Trials Logo

Infarction clinical trials

View clinical trials related to Infarction.

Filter by:

NCT ID: NCT02133521 Terminated - Clinical trials for Acute Ischemic Stroke

DLBS1033 for Acute Ischemic Stroke Patients

ADDLIST
Start date: November 11, 2014
Phase: Phase 2/Phase 3
Study type: Interventional

This is a prospective, randomized, double-blind, and controlled clinical study to investigate the effects of DLBS1033 in conjunction with standard therapy compared to standard therapy alone in acute ischemic stroke patients. It is hypothesized that the improvement in functional outcomes as measured by NIHSS and BI as well as the improvement in haemostatic parameters as measured by thrombocyte aggregation test (TAT), fibrinogen, and d-dimer in DLBS group will be significantly greater than those in the control group.

NCT ID: NCT02121158 Terminated - Clinical trials for Coronary Artery Disease

Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly

I-70
Start date: August 7, 2015
Phase: N/A
Study type: Interventional

The overall aim of this trial is to study the safety and efficacy of ICD implantation as a primary prevention strategy of sudden cardiac death in patients 70 years and older. This study will assess the many competing factors involved with ICD implantation including 1) the impact on mortality, especially in the context of a declining rate of sudden death with advanced age, 2) the tolerability of the powerful therapeutic action of the device, and 3) the impact on quality of life.

NCT ID: NCT02093377 Terminated - Clinical trials for Acute Myocardial Infarction

ASV for Sleep Apnea After Myocardial Infarction

TEAM-ASV-I
Start date: February 2014
Phase: N/A
Study type: Interventional

The aim of this randomized controlled trial is to test the effect of 12 weeks Adaptive Servo-Ventilation (ASV) therapy (additionally to optimal medical management of myocardial infarction) on myocardial salvage (MSI=myocardial salvage/area at risk, primary endpoint).

NCT ID: NCT02075125 Terminated - Clinical trials for ST-Segment Elevation Myocardial Infarction

Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction

Start date: January 2014
Phase: Phase 3
Study type: Interventional

To compare efficacy and safety of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

NCT ID: NCT02063425 Terminated - Cerebral Infarction Clinical Trials

"Evaluation by Transcranial Magnetic Stimulation of the Benefit of Fluoxetine on Motor Recovery After Stroke"

EFLUSTIM
Start date: February 2014
Phase: N/A
Study type: Interventional

The objective of this study is to better characterize the mechanisms of action of fluoxetine in motor recovery and more specifically to identify the neurophysiological substrate underlying fluoxetine-induced motor recovery in stroke. In this study, the investigators propose to use transcranial magnetic stimulation (TMS) to assess the effect of a chronic treatment of fluoxetine on corticospinal excitability and integrity.

NCT ID: NCT02037412 Terminated - Clinical trials for Acute Coronary Syndrome

Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome

Start date: January 2014
Phase: Phase 4
Study type: Interventional

The investigators hypothesized that ticagrelor may enhance endothelial healing after DES implantation by increasing adenosine concentrations by the inhibition of adenosine uptake into erythrocytes, compared to clopidogrel. Thus, the investigators will evaluate the extent of endothelialization (stent strut coverage) and neointimal hyperplasia (neointimal thickness) 3 months after DES implantation by optical coherence tomography (OCT)

NCT ID: NCT02021487 Terminated - Clinical trials for ST Elevatation Myocardial Infarction (STEMI)

Prokinecitine in Acute Myocardial Infarction

Prok-Idm
Start date: November 2013
Phase:
Study type: Observational

The study aims to investigate the presence of a substance in the blood called prokinecitine, which is released by the heart when a heart attack occurs. Several venous blood samples at the arm are withdrawn at admission, H6, H12, H24, H48 and H72 in order to measure the concentration of this substance in the blood. The usefulness of this new blood marker is going to be determsined to seek if it would be of help to better diagnose or estimate the gravity of heart infarction after a heart attack.

NCT ID: NCT02002234 Terminated - Infarction Clinical Trials

Hemicraniectomy for Malignant Middle Cerebral Artery Infarction (HeMMI)

HeMMI
Start date: January 2002
Phase: N/A
Study type: Interventional

A single-centered, randomized, controlled clinical trial comparing standardized medical care alone with standardized medical care and decompressive hemicraniectomy to determine the effectiveness of decompressive surgery more definitively in patients with clinical signs of infarction of the Middle Carotid Artery (MCA) territory.

NCT ID: NCT01972126 Terminated - Clinical trials for Acute Myocardial Infarction

MAGNetic QRS-Fragmentation in Patients With Myocardial InfarcTion and Moderately RedUceD Ejection Fraction

MAGNITUDE
Start date: September 2013
Phase: N/A
Study type: Observational

The MAGNetic QRS-Fragmentation in Patients with Myocardial InfarcTion and Moderately RedUceD Ejection Fraction (MAGNITUDE) study will assess in MI survivors with moderately reduced left ventricular function, whether non-invasive MFI QRS Fragmentation alone or in combination with parameters derived from a Holter recording can be used to identify a group of patients at high risk for SCD/life threatening ventricular arrhythmia.

NCT ID: NCT01969890 Terminated - Clinical trials for Left Ventricular Systolic Dysfunction

STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial

STEM-AMI
Start date: October 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that granulocyte colony-stimulating factor (G-CSF) therapy in addition to state-of-the-art treatment (pharmacological and non pharmacological) is safe and significantly improves clinical outcome in patients with reduced left ventricular ejection fraction (LVEF) (≤45%) after successful reperfusion for large anterior acute myocardial infarction.